Analyzing Adaptimmune Therapeutics (ADAP) and Nantkwest (NK)

Adaptimmune Therapeutics (NASDAQ: ADAP) and Nantkwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

59.7% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Nantkwest shares are held by institutional investors. 26.5% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 72.3% of Nantkwest shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Adaptimmune Therapeutics and Nantkwest’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptimmune Therapeutics $37.83 million 32.35 -$70.13 million ($0.80) -16.25
Nantkwest $50,000.00 4,576.07 -$96.42 million ($1.20) -2.44

Adaptimmune Therapeutics has higher revenue and earnings than Nantkwest. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Nantkwest, indicating that it is currently the more affordable of the two stocks.


This table compares Adaptimmune Therapeutics and Nantkwest’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics -160.83% -32.57% -24.93%
Nantkwest -254,940.98% -43.71% -37.53%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Adaptimmune Therapeutics and Nantkwest, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptimmune Therapeutics 0 0 4 0 3.00
Nantkwest 1 1 0 0 1.50

Adaptimmune Therapeutics presently has a consensus price target of $19.33, suggesting a potential upside of 48.72%. Nantkwest has a consensus price target of $3.00, suggesting a potential upside of 2.39%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than Nantkwest.

Volatility and Risk

Adaptimmune Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Nantkwest has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500.


Adaptimmune Therapeutics beats Nantkwest on 10 of the 13 factors compared between the two stocks.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

Nantkwest Company Profile

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply